Alvotech (NASDAQ:ALVO) Stock Price Up 4.8% – Still a Buy?

Alvotech (NASDAQ:ALVO – Get Free Report) rose 4.8% on Monday. The company traded as high as $4.32 and last traded at $4.39. Approximately 110,448 shares traded hands during trading, a decline of 86% from the average daily volume of 779,760 shares. The stock had previously closed at $4.19.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen raised Alvotech from a “sell” rating to a “hold” rating in a report on Sunday. UBS Group set a $8.00 price objective on Alvotech in a report on Wednesday, September 16th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Jefferies Financial Group initiated coverage on Alvotech in a report on Tuesday, November 10th. They set a “buy” rating and a $9.00 target price for the company. Finally, Bank of America started coverage on shares of Alvotech in a research report on Monday, August 24th. They issued a “buy” rating and a $7.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Alvotech presently has an average rating of “Hold” and a consensus price target of $8.40.

Check Out Our Latest Stock Analysis on Alvotech

Alvotech Trading Up 5.8%

The stock has a market cap of $1.34 billion, a P/E ratio of -5.41 and a beta of 0.24. The stock has a 50 day simple moving average of $5.23 and a 200 day simple moving average of $4.20.

Alvotech (NASDAQ:ALVO – Get Free Report) last released its earnings results on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $111.60 million for the quarter, compared to the consensus estimate of $123.45 million. Equities analysts anticipate that Alvotech will post -0.01 earnings per share for the current year.

Institutional Trading of Alvotech

A number of institutional investors and hedge funds have recently made changes to their positions in ALVO. Marshall Wace LLP bought a new position in Alvotech in the third quarter valued at approximately $2,326,000. State Street Corp acquired a new position in Alvotech during the third quarter valued at approximately $594,000. Royce & Associates LP bought a new stake in Alvotech during the third quarter worth $3,817,000. Commonwealth Equity Services LLC bought a new stake in Alvotech during the third quarter worth $69,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Alvotech during the third quarter worth $100,000.

Alvotech Company Profile

(Get Free Report)

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.

See Also

Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.